{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:24:58Z","timestamp":1791516298272,"version":"4.3.4"},"reference-count":18,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some patients do not benefit from therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the correlation between perianal fistula healing and trough levels of infliximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross\u2010sectional study, we identified patients with Crohn's disease who had perianal fistulas and were treated with infliximab for at least 24\u00a0weeks. We excluded patients who underwent a faecal diversion procedure or proctectomy. Predictive variables included demographics, disease phenotype, disease activity, infliximab levels, anti\u2010infliximab antibodies. The primary outcome was fistula healing defined as the absence of drainage. The secondary outcome was complete fistula closure and mucosal healing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      117 patients were included. Patients with fistula healing had significantly higher median serum infliximab levels when compared to those with active fistulas [15.8 vs. 4.4\u00a0\u03bcg\/mL, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001)]. There was an incremental gain in fistula healing with higher infliximab levels. The\n                      <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                      for the association between fistula healing and infliximab levels was 0.82 (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001), while the\n                      <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                      for the association of infliximab levels and fistula closure was 0.69 (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.014). Patients with anti\u2010infliximab antibodies had a lower chance of achieving fistula healing (\n                      <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\n                      : 0.04 [95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      : 0.005\u20130.3],\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is a significant association between serum infliximab levels and rates of fistula healing. Achieving infliximab levels \u226510.1\u00a0mcg\/mL in patients with Crohn's disease and perianal fistulas may improve outcomes as part of a treat\u2010to\u2010target strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.13970","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T05:32:42Z","timestamp":1487309562000},"page":"933-940","source":"Crossref","is-referenced-by-count":291,"title":["Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-5555","authenticated-orcid":false,"given":"A. J.","family":"Yarur","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kanagala","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Stein","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Czul","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Department of Medicine University of Miami Miller School of Medicine  Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Quintero","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Department of Medicine University of Miami Miller School of Medicine  Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Best","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fox","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Idstein","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine Medical College of Wisconsin  Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Abreu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Department of Medicine University of Miami Miller School of Medicine  Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32362"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.5.696"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04486.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.06.025"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.10.025"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.12.026"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05057.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13754"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2012.06.002"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00877-1"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05990.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjw182"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307883"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308099"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13970","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T23:38:04Z","timestamp":1694389084000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/apt.13970"],"URL":"https:\/\/doi.org\/10.1111\/apt.13970","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727315173.793562763","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]}}}